Clinical

Dataset Information

0

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy


ABSTRACT: The purpose of this study is to evaluate the dose-limiting toxicity (DLT), toxicity profile, maximum tolerated dose (MTD) and characterize the pharmacokinetics of biweekly PEP02 treatment.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2075260 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2015-11-11 | GSE66999 | GEO
2009-04-01 | GSE12062 | GEO
| 2520710 | ecrin-mdr-crc
| 2063458 | ecrin-mdr-crc
| 2624760 | ecrin-mdr-crc
2018-08-26 | GSE82161 | GEO
| 2518758 | ecrin-mdr-crc
2024-01-26 | PXD044740 | Pride
2022-08-02 | E-MTAB-5922 | biostudies-arrayexpress
| 2378840 | ecrin-mdr-crc